Posts filtered by tags: Covid-19 Vaccine[x]


 

One of Belgium's top virologists offered his family 4 tips for surviving the long COVID-19 winter — read the full letter he wrote them

Guido Vanham and his son Peter Vanham. Peter Vanham Guido Vanham is a virologist, a microbiologist who studies the rapid spreading of viruses, who's been sending letters to his three children throughout the coronavirus pandemic. The text of his most recent letter is printed below with permission from his son, Peter Vanham. In it, Guido Vanham writes that he's optimistic about the latest major vaccine trial updates but warns that if history and previous viruses are any guide, the toughest t...
Tags: Europe, Science, News, Holidays, Opinion, Trends, Belgium, Pfizer, Nordic, Peter, World Economic Forum, Don, Geneva Switzerland, Antwerp Belgium, Nele, Moderna


Moderna's CEO sold nearly $2 million of his stock ahead of the company's emergency use vaccine filing. He's now worth $3 billion.

Moderna CEO, Stephane Bancel. Andrew Dunn/Business Insider Moderna CEO Stephane Bancel sold almost $2 million in shares ahead of the company's emergency use authorization filing for its COVID-19 vaccine.Bancel sold a total of 19,000 shares between November 18-19 as part of a predetermined trading plan amended May 21, according to a filing with the SEC.Moderna is the second major drug company to announce success in a late-stage COVID-19 vaccine trial. It expects to file for FDA approval by t...
Tags: Trends, Markets, Billionaires, SEC, Stocks, Fda, Pfizer, Goldman, Pharmaceutical, Pharma Company, Moderna, Healthcare Stocks, Stéphane Bancel, Albert Bourla, Coronavirus, Bancel


Oxford and AstraZeneca's COVID-19 vaccine is considerably cheaper and easier to distribute than either Pfizer's or Moderna's. Here's why.

A half-dose of Oxford-AstraZeneca's COVID-19 vaccine initially could mean we have double the number doses available when it's approved by regulators. Siphiwe Sibeko/Pool via AP The University of Oxford and AstraZeneca's COVID-19 vaccine can be stored at normal fridge temperatures for at least six months. Unlike Pfizer and BioNTech's vaccine, it therefore doesn't require an ultra-cold storage and transport system, making it cheaper to distribute globally. The price per dose is also ...
Tags: Minnesota, US, Trends, Eu, Healthcare, Oxford, Astrazeneca, Pfizer, Vaccine, University of Oxford, Oxford University, Welt am Sonntag, Andrew Pollard, Moderna, Siphiwe Sibeko, Stéphane Bancel


Moderna planning to charge governments $25-$37 for its COVID-19 vaccine

https://www.financialexpress.com/lifestyle/health/moderna-to-charge-25-37-for-covid-19-vaccine-ceo/2133774/ Moderna’s CEO Stephane Bancel has announced that they are planning to charge $25-$37 (depending on the quantity ordered) for their Covid-19 vaccine. He was reportedly quoted saying “Our vaccine therefore costs about the same as a flu shot, which is between $10 and $50.”  Moderna had earlier announced that it has developed a new vaccine for Covid-19 and the vaccine was 94.5% effective in pr...
Tags: Business, News, Moderna, Stéphane Bancel, Covid-19 Vaccine


FDA advisory committee to discuss emergency authorization for Pfizer's COVID-19 vaccine

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. Sarah Silbiger/Getty Images An FDA advisory committee will meet next month to discuss an emergency use authorization (EUA) for Pfizer's COVID-19 vaccine. Earlier this week, Pfizer said clinical trials had shown its vaccine to be 95% effective. "While we cannot predict how long the FDA's review will take, the FDA will review the request as expeditiously as possible, while...
Tags: Science, US, Trends, Food And Drug Administration, Fda, Pfizer, Charles Davis, US Food and Drug Administration, EUA, ECRI, White Oak Maryland, Stephen M Hahn, COVID, Covid-19 Vaccine, Sarah Silbiger Getty, Marcus Schabacker


Pfizer, BioNTech gain after saying they'll submit their COVID-19 vaccine to the FDA for emergency approval

Dogukan Keskinkilic/Anadolu Agency via Getty Images Pfizer and BioNTech gained on Friday after saying they would submit their COVID-19 vaccine candidate to the FDA today for Emergency Use Authorization.The submission will potentially enable use of the vaccine in high-risk populations in the US by the middle to end of December, the companies said.The companies will be ready to distribute the vaccine within hours after authorization and expect to produce up to 50 million doses of its vaccine...
Tags: US, Trends, Markets, Tesla, Fda, Pfizer, Movers, Matthew Fox, Rob Arnott, BioNtech, Ashley Wilson, Mover, COVID-19, Covid-19 Vaccine, Pfizer BioNTech, Pfizer Stock


Inside the COVID-19 vaccine airlift: How cargo carriers plan to distribute the world's soon-to-be most valuable drugs to market

Cargo planes will be crucial is getting a COVID-19 vaccine to the furthest reaches of the world in the shortest time. Oed/ullstein bild/Getty Air cargo carriers are gearing up to transport a vaccine for the novel coronavirus if one is approved, in the second COVID-19 airlift of 2020. Each vaccine comes with its own requirements for shipping, with Pfizer's being among the most challenging as it requires storage temperatures of -94 degrees Fahrenheit, presenting a problem for aircraft. Vacci...
Tags: Travel, Transportation, Europe, News, Air Travel, Planes, US, Trends, Atlanta, Flying, Netherlands, Emirates, Dubai, Belgium, Aviation, Michigan


Coronavirus vaccine research and distribution plans overlook an important, growing group: people who already got sick

Kate Bingham, Chair of the UK government's Vaccine Taskforce, starts her Novavax trial at the Royal Free Hospital in London. Kirsty O'Connor/PA Images via Getty Images US public-health experts aren't sure when Americans who've survived the coronavirus will be eligible for a vaccine. Some leading trials — including Moderna's — excluded anyone with a history of coronavirus infection, so researchers don't yet know how a vaccine would affect those people. Without that data, experts say...
Tags: UK, Science, London, News, Washington, Massachusetts, US, Trends, Italy, Pfizer, Centers For Disease Control And Prevention, Indiana University, Johnson Johnson, National Academy of Sciences, Lambert, Rockefeller University


Moderna's CEO says vaccines aren't a 'silver bullet,' people must still social distance and wear masks

Moderna CEO Stephane Bancel attends a meeting with President Donald Trump. Andrew Harnik/AP Images Wearing a mask and social distancing are the "best weapon" to control the virus, according to Moderna CEO Stéphane Bancel. Bancel spoke at the Bloomberg New Economy Forum on Thursday.  Moderna recently announced that its experimental vaccine was 94.5% effective against the new coronavirus. Bancel said in a recent interview with Business Insider that the public will have access to a vaccine by...
Tags: News, US, Trends, Bloomberg, Healthcare, Fda, Anthony Fauci, Chinese Center for Disease Control and Prevention, Moderna, Stéphane Bancel, Bloomberg New Economy Forum, Allana Akhtar, Coronavirus, Bancel, Coronavirus Vaccine, Covid-19 Vaccine


Operation Warp Speed bought 100 million doses of Pfizer's and Moderna's vaccines before results came in. That $3.5 billion bet is paying off.

President Donald Trump delivers remarks on Operation Warp Speed. Shealah Craighead, White House The US launched Operation Warp Speed, an initiative to deliver coronavirus shots to Americans, in May. The program has funded the manufacturing of six promising vaccine candidates while clinical trials are ongoing. That includes shots from Pfizer and Moderna. Both companies recently announced positive results from their final stage of clinical trials. Warp Speed plans to distribute doses as soon...
Tags: Science, News, Cdc, White House, US, Trends, Department Of Defense, Bloomberg, European Union, Joe Biden, Ap, New York Times, Wisconsin, World Health Organization, Michigan, Fda


AstraZeneca gains after study suggests its COVID-19 vaccine produced immune response in elderly

Steve Parsons-WPA Pool/Getty Images AstraZeneca's COVID-19 vaccine demonstrated a strong immune response in elderly patients, according to a study from the University of Oxford.Data from the Phase II vaccine trial was published in the Lancet medical journal on Thursday."This is a very important step, because the big worry with any vaccine is that it doesn't work so well in older people," the Lancet's editor in chief told Bloomberg.Visit Business Insider's homepage for more stories.Another ...
Tags: Europe, UK, Finance, Time, Trends, Investing, Markets, Healthcare, Trading, Astrazeneca, Stocks, Pfizer, University of Oxford, Stock Market, Lancet, Biotechnology


Oxford's COVID-19 vaccine is safe and produces an immune response in older adults, encouraging early trial results suggest

Kate Bingham, Chair of the Government's Vaccine Taskforce, after starting her Novavax trial at the Royal Free Hospital, north London on October 13, 2020. Kirsty O'Connor/PA Images via Getty Images Early trial results published in The Lancet suggest The University of Oxford and AstraZeneca's COVID-19 vaccine produces an immune response and is safe in older adults. This is important because older adults are more likely to develop severe cases of the virus, and some vaccines aren't as...
Tags: UK, Science, London, Trends, Healthcare, Oxford, Astrazeneca, Pfizer, Vaccine, University of Oxford, Oxford University, Today programme, Pollard, Royal Free Hospital, Novavax, Andrew Pollard


Pfizer's and Moderna's vaccines likely work for all existing coronavirus strains. Don't worry about mutations for now, scientists say.

Mustafa Gerek participates in a coronavirus vaccine trial at Ankara City Hospital in Ankara, Turkey, October 13, 2020. Aytac Unal/Anadolu Agency via Getty Images The coronavirus vaccine candidates from Pfizer and Moderna both prevented COVID-19 in clinical trials. Research suggests the coronavirus is genetically stable, which means it mutates very slowly. So the leading vaccines should work well long-term against all strains of the virus. By contrast, viruses like the flu accumulate geneti...
Tags: Health, Science, News, China, Trends, Paris, Switzerland, Fda, Pfizer, Vaccines, Seattle, Mutations, Wuhan, Mount Sinai, Don, Bedford


When can I get a coronavirus vaccine?

Jakub Porzycki/NurPhoto via Getty Images Both Moderna and Pfizer have recently delivered promising news that their coronavirus vaccines are highly effective, in large, diverse human trials. But that doesn't mean you're going to be able to get a shot before the end of 2020.  In all likelihood, the first coronavirus vaccines will begin rolling out to frontline workers and vulnerable populations in the last days of 2020, or possibly early 2021. By Memorial Day in late May, it's possible that...
Tags: Science, News, Cdc, White House, US, Trends, Public Health, South Africa, New York Times, Vaccination, Fda, Pfizer, Anthony Fauci, Istanbul, Soweto, Ankara Turkey


Pfizer picks 4 US states to trial transporting its COVID-19 vaccine at temperatures far below freezing. It's a key test of the 'cold chain' the vaccine will rely on.

A volunteer receives an experimental vaccination for the coronavirus as part of a Pfizer clinical trial at the University of Maryland's medical school. University of Maryland Pfizer is piloting delivery options for its COVID-19 vaccine in Rhode Island, Texas, New Mexico, and Tennessee, Reuters reported Tuesday. The vaccine has to be shipped and stored at minus 94 degrees Fahrenheit, which poses major distribution challenges. Moderna's vaccine, by comparison, can be stored in a fridge. ...
Tags: Texas, US, Trends, Tennessee, Healthcare, Ubs, Pfizer, Vaccine, New Mexico, Rhode Island, Reuters, Tennessee Reuters, Moderna, Coronavirus, COVID-19, Coronavirus Vaccine


I volunteered to test the Moderna coronavirus vaccine. Here's what the experience was like — and why it's given me hope for the world.

Elle Hardy. Elle Hardy Journalist Elle Hardy is taking part in a phase-three trial of Moderna's mRNA-1273 vaccine, which just announced it's 94.5% effective against coronavirus. The federal government announced in August that it would spend $1.53 billion to buy 100 million doses of the vaccine, with an option to purchase up to 400 million additional doses. After a slight reaction to the two doses, Hardy said she was certain she didn't receive a placebo.  A recent antibody test confirmed sh...
Tags: Health, South Korea, England, Instagram, Australia, White House, US, Trends, United States, Healthcare, Oxford, MMR, Vaccine, Donald Trump, Nordic, Hardy


Pfizer and AstraZeneca slide as Moderna's rival COVID-19 vaccine shows strong efficacy

Joe Raedle/Getty Images Strong preliminary data results from Moderna's COVID-19 vaccine has spurred a selloff in rival vaccine developers Pfizer, BioNTech, and AstraZeneca.Moderna said on Monday that its COVID-19 vaccine candidate demonstrated an efficacy rate of 94.5% in a trial of more than 30,000 patients.Last week, Pfizer and its partner BioNTech said its COVID-19 vaccine candidate demonstrated an efficacy rate of more than 90% in a trial of 44,000 patients.AstraZeneca could release in...
Tags: Trends, Markets, Trading, Astrazeneca, Stocks, Fda, Pfizer, University of Oxford, Stock Market, Goldman, Movers, Joe Raedle Getty, Matthew Fox, Moderna, Peter Kraus, AllianceBernstein


A scientist who helped make the Pfizer vaccine predicted life being back to normal within a year if enough people take it

Ugur Sahin, the CEO of BioNTech, in November 2019. Andreas Arnold/picture alliance via Getty Images The head of the company that helped created Pfizer's effective coronavirus said life could be "normal" within a year if enough people are vaccinated. Professor Ugur Sahin, the chief executive of German company BioNTech, told the BBC that high vaccine update may mean "we could have a normal winter next year." He said the number of vaccines under development means he is "confident" that hurdle...
Tags: Science, US, Trends, Bbc, News UK, Andrew Marr, Pfizer, Anthony Fauci, Sahin, Cincinnati Children, Moderna, BioNtech, Coronavirus, COVID-19, Coronavirus Vaccine, Covid-19 Vaccine


Sell stocks into strength on any COVID-19 vaccine news as 2021 turns into a bear market, BofA says

Lucas Jackson/Reuters Peak positioning, peak policy, and peak profits are three reasons why investors should sell their stocks into strength on any COVID-19 news in the coming months, Bank of America said on Friday.The bank likened today's scenario to 2018, when US tax cuts caused a temporary peak in investor positioning, fiscal policy, and corporate profits in the first half of that year."We are sellers-into-strength into vaccine [rollout] in coming months," it said.Despite the negative o...
Tags: Finance, US, Trends, Markets, Bank Of America, Trading, Stocks, Stock Market, Goldman, Trump, BofA, Matthew Fox, COVID-19, Covid-19 Vaccine, Stock Market Outlook, Stock Market Analysis


Volunteers testing Pfizer’s new Covid-19 vaccine are complaining of 'severe' hangover and aches after their first shot

https://www.businesstoday.in/sectors/pharma/pfizer-90-effective-covid-vaccine-leaves-volunteers-with-severe-hangover-aches/story/421946.htmlPfizer had earlier claimed 90% efficacy of the drug after analyzing data from phase III clinical trials. The post Volunteers testing Pfizer’s new Covid-19 vaccine are complaining of 'severe' hangover and aches after their first shot appeared first on NextBigWhat.
Tags: Business, News, Pfizer, Covid-19 Vaccine


Pfizer's vaccine relies on a 'cold chain' that keeps the shots colder than a freezer. Here's how it works.

Pfizer and BioNTech 's vaccine must be kept at ultra-cold temperatures on its journey from the production line to a patient's arm. Pfizer developed a suitcase-sized box that uses dry ice to keep between 1,000 and 5,000 doses for 10 days at minus 70 degrees Celsius. Leon Neal/Getty Images Pfizer's new coronavirus vaccine will need to be kept hyper-cold, at -94 degrees Fahrenheit, as it is shipped around the globe. That could make it difficult to get the vaccine distributed, especial...
Tags: England, Science, News, Nbc, Cdc, Russia, US, Trends, Public Health, Pfizer, Vaccines, Wall Street Journal, Business Insider, Reuters, US Food and Drug Administration, Sanofi


DHL and other logistics companies bolster cold storage supply chains in the wake of hopeful COVID-19 vaccination trials announced by Pfizer and BioNTech

This photo Illustration taken in Tehatta, India, on November 10, 2020 show the Pfizer's products. Pfizer's experimental COVID-19 vaccine appears to be working. The vaccine was found to be more than 90% effective, according to clinical results released by the company yesterday. Photo Illustration by Soumyabrata Roy/NurPhoto via Getty Images The eventual approval of successful COVID-19 vaccines will necessitate the largest vaccine distribution program in history. For th...
Tags: Asia, China, Southeast Asia, India, US, Trends, Getty Images, UPS, Asia Pacific, Netherlands, Korea, Vaccinations, Pfizer, DHL, Bain Company, McKinsey and Company


Dozens of pharmacies, including those inside Walmart, Costco, and Kroger stores, will now be able to administer COVID vaccines when they're available

HHS: Pharmacists in CVS, Costco, Walmart, and Rite Aid will be able to provide the eventual COVID-19 vaccine. Kirsty O'Connor/PA Images via Getty Images The US Department of Health and Human Services just announced a partnership with large pharmacy chains to distribute an eventual COVID-19 vaccine.  The list of chain pharmacies includes CVS, Costco, Walmart, Rite Aid, Publix, Walgreens and Kroger.  There is not currently an approved vaccine for the new coronavirus. Pfizer this week sai...
Tags: News, US, America, Trends, Walmart, Joe Biden, Healthcare, World Health Organization, Medicare, Fda, Pfizer, Costco, Cvs, Kroger, Trump, HHS


Kids may produce a weaker antibody response to the coronavirus than adults do — which could explain why their infections are milder

Children wear masks in Spain. Europa Press News/Getty Images Children mount a weaker antibody response to the coronavirus than adults, a recent study found. The finding indicates that children may clear the virus before it replicates widely in their bodies. Children may also benefit from an immune-system memory response to other coronaviruses. Scientists still expect kids to have some long-term immunity and respond to a vaccine. Visit Business Insider's homepage for more stories. Researche...
Tags: Science, News, Children, Trends, Spain, Columbia University, Antibodies, Columbia, New York City Some, Immunity, John Moore Getty, Farber, Irving Medical Center, Aria Bendix, Coronavirus, Covid-19 Vaccine


The US could be on track to hit 1 million daily coronavirus cases by the end of 2020, a new report finds

Healthcare worker Dante Hills passes paperwork to a woman at a COVID-19 testing site in Miami, Florida. Lynne Sladky/AP Photo The US could see 1 million daily coronavirus cases by the end of 2020, according to a new report from Pantheon Macroeconomics. That's based on the current trend of average cases rising 34% from week to week. Experts predict this surge could be the largest, and perhaps deadliest, yet. Visit Business Insider's homepage for more stories. In March, when New York City ho...
Tags: Texas, Science, News, New York City, Brown University, US, Trends, Joe Biden, Pennsylvania, United States, South Dakota, Washington Dc, Healthcare, Michigan, New Mexico, Biden


Pfizer's CEO cashed out 60% of his stock on the same day the company unveiled the results of its COVID-19 vaccine trial

Pfizer CEO Albert Bourla. AP Photo/Pablo Martinez Monsivais Pfizer chief executive Albert Bourla sold 62% of his stock in the company on the same day the drugmaker announced the results of its COVID-19 vaccine trial.Bourla sold $5.6 million in stock on Monday as part of a predetermined trading plan adopted on August 19.His stock sale was carried out at $41.94 a share. The 52-week-high for Pfizer stock is $41.99, which means the CEO cashed out his shares close to their highest this year.Pfiz...
Tags: Trends, Markets, Vaccination, Pfizer, Securities And Exchange Commission, Stock Options, US Food and Drug Administration, BioNtech, Albert Bourla, Bourla, Stock Sale, Coronavirus, COVID-19, Covid-19 Vaccine, Covid And Stocks, Vaccine News


Fauci says all Americans could have access to a COVID-19 vaccine by April

Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases. AP Photo/Alex Brandon A COVID-19 vaccine could be available to all Americans as soon as April, Dr. Anthony Fauci, the US's leading infectious-disease expert, told CNN on Tuesday. Authorities will most likely offer any available vaccine doses to frontline healthcare workers first, he said, followed by older people and others considered most vulnerable to severe disease. But he expressed concerns th...
Tags: US, Trends, Cnn, Healthcare, Fda, Pfizer, Anthony Fauci, Centers For Disease Control And Prevention, Fauci, National Academy of Medicine, Alex Brandon, Azar, BioNtech, Alex Azar, Coronavirus, COVID-19


Fauci says all Americans could have access to a COVID-19 vaccine by April 2021

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. AP Photo/Alex Brandon A COVID-19 vaccine could be available to all Americans as early as April 2021, Dr. Anthony Fauci, the US' leading infectious-disease expert, told CNN Tuesday. Authorities will likely offer a COVID-19 to frontline healthcare staff first, he said, followed by the elderly and other vulnerable people. But he expressed concerns that not everyone may want to get vaccinated as soon as a...
Tags: Cdc, US, Trends, Cnn, Healthcare, Fda, Pfizer, Anthony Fauci, Health And Human Services, Centers for Disease Control and Prevention CDC, Fauci, National Academy of Medicine, Alex Brandon, ACIP, Azar, Advisory Committee on Immunization Practices ACIP


Donald Trump and his son Donald Trump Jr., without evidence, accuse Pfizer of deliberately waiting until after Election Day to release its COVID-19 vaccine trial results

Samuel Corum/Getty Images, Tasos Katopodis/Getty Images President Donald Trump and his son Donald Trump Jr. on Monday baselessly accused Pfizer of deliberately waiting until after the US election to announce the promising early results of its COVID-19 vaccine trials. Pfizer CEO Albert Bourla on Monday told CNN that Pfizer had simply released the results "when the science told us the data was available." Though the announcement came Monday from Pfizer, and not a government organization, Tr...
Tags: Politics, Science, White House, US, Trends, Joe Biden, Cnn, Healthcare, Fda, Pfizer, Donald Trump, Trump, Mike Pence, Donald J Trump, US Food and Drug Administration, Donald Trump Jr


Donald Trump and Trump Jr. spread a conspiracy theory that Pfizer deliberately waited until after Election Day to release its COVID-19 vaccine trial results

Samuel Corum/Getty Images, Tasos Katopodis/Getty Images President Donald Trump and his son Donald Trump Jr. on Monday accused Pfizer of deliberately waiting until after the election to announce the promising early results of its COVID-19 vaccine trials. Trump said that both the US Food and Drug Administration and the Democrats "didn't want to have me get a Vaccine WIN, prior to the election, so instead it came out five days later." Trump Jr. suggested the timing of Pfizer's results, which...
Tags: Politics, Science, White House, US, Trends, Joe Biden, Cnn, Daily Mail, Healthcare, Fda, Pfizer, Donald Trump, Trump, Mike Pence, Donald J Trump, US Food and Drug Administration